Colorectal cancer (CRC) presents a significant health challenge, especially with rare genetic variations complicating treatment.
VC firm venBio secures $528M for ‘extremely selective’ fifth fund after recent IPOs, M&A exits
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS